“The notion that we have to see a patient in front of us every time in order to have a billable encounter is antiquated,” says Gary Kirsh, MD.
In an interview at the 2021 LUGPA Annual Meeting, Gary Kirsh, MD, chair, LUGPA Political Affairs Committee and president, The Urology Group, discussed the latest developments in telehealth reimbursement for urologists.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.